{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:51Z","timestamp":1791357471197,"version":"4.3.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T00:00:00Z","timestamp":1371513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s40264-013-0074-2","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T13:00:44Z","timestamp":1371474044000},"page":"663-671","source":"Crossref","is-referenced-by-count":26,"title":["Profile of Sexual and Genitourinary Treatment-Emergent Adverse Events Associated with Atomoxetine Treatment: A Pooled Analysis"],"prefix":"10.1007","volume":"36","author":[{"given":"Angelo","family":"Camporeale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen Ann","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody","family":"Arsenault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas K.","family":"Kelsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,18]]},"reference":[{"key":"74_CR1","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Press; 2000."},{"key":"74_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2001.tb05770.x","volume":"931","author":"PH Wender","year":"2001","unstructured":"Wender PH, Wolf LE, Wasserstein J. Adults with ADHD: an overview. Ann N Y Acad Sci. 2001;931:1\u201316.","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"74_CR3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.4088\/JCP.v65n1003","volume":"65","author":"TE Wilens","year":"2004","unstructured":"Wilens TE, Dodson W. A clinical perspective of attention-deficit\/hyperactivity disorder into adulthood. J Clin Psychiatry. 2004;65(10):1301\u201313.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"74_CR4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/archpsyc.63.6.669","volume":"63","author":"RC Kessler","year":"2006","unstructured":"Kessler RC, Coccaro EF, Fava M, et al. The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63(6):669\u201378.","journal-title":"Arch Gen Psychiatry"},{"key":"74_CR5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1192\/bjp.bp.106.034389","volume":"190","author":"J Fayyad","year":"2007","unstructured":"Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402\u20139.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"74_CR6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1176\/appi.ajp.163.4.716","volume":"163","author":"RC Kessler","year":"2006","unstructured":"Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716\u201323.","journal-title":"Am J Psychiatry"},{"issue":"Suppl. 12","key":"74_CR7","first-page":"10","volume":"63","author":"RA Barkley","year":"2002","unstructured":"Barkley RA. Major life activity and health outcomes associated with attention-deficit\/hyperactivity disorder. J Clin Psychiatry. 2002;63(Suppl. 12):10\u20135.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"74_CR8","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1542\/peds.108.5.e83","volume":"108","author":"D Michelson","year":"2001","unstructured":"Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83.","journal-title":"Pediatrics"},{"issue":"11","key":"74_CR9","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1176\/appi.ajp.159.11.1896","volume":"159","author":"D Michelson","year":"2002","unstructured":"Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896\u2013901.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"74_CR10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000188869.58300.a7","volume":"65","author":"AJ Allen","year":"2005","unstructured":"Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65(12):1941\u20139.","journal-title":"Neurology"},{"issue":"1","key":"74_CR11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.114.1.e1","volume":"114","author":"DK Kelsey","year":"2004","unstructured":"Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit\/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1\u20138.","journal-title":"Pediatrics"},{"issue":"2","key":"74_CR12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-3223(02)01671-2","volume":"53","author":"D Michelson","year":"2003","unstructured":"Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112\u201320.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"74_CR13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/JCP.0b013e318192e4a0","volume":"29","author":"LA Adler","year":"2009","unstructured":"Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit\/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009;29(1):44\u201350.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"74_CR14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/WNF.0b013e31820c00eb","volume":"34","author":"JL Young","year":"2011","unstructured":"Young JL, Sarkis E, Qiao M, et al. Once-daily treatment with atomoxetine in adults with attention-deficit\/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2011;34(2):51\u201360.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"74_CR15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/1087054709342203","volume":"13","author":"T Durell","year":"2010","unstructured":"Durell T, Adler L, Wilens T, et al. Atomoxetine treatment for ADHD: younger adults compared with older adults. J Atten Disord. 2010;13(4):401\u20136.","journal-title":"J Atten Disord"},{"issue":"6","key":"74_CR16","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1089\/cap.2008.074","volume":"19","author":"LA Wietecha","year":"2009","unstructured":"Wietecha LA, Williams DW, Herbert M, et al. Atomoxetine treatment in adolescents with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(6):719\u201330.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"74_CR17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/da.20549","volume":"26","author":"LA Adler","year":"2009","unstructured":"Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit\/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009;26(3):212\u201321.","journal-title":"Depress Anxiety"},{"key":"74_CR18","unstructured":"Strattera\u00ae (atomoxetine). US prescribing information. Indianapolis: Eli Lilly and Company; 2011."},{"issue":"5","key":"74_CR19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0893-133X(02)00346-9","volume":"27","author":"FP Bymaster","year":"2002","unstructured":"Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit\/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699\u2013711.","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"74_CR20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0024-3205(93)90194-8","volume":"52","author":"C Bolden-Watson","year":"1993","unstructured":"Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 1993;52(12):1023\u20139.","journal-title":"Life Sci"},{"issue":"2\u20133","key":"74_CR21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(97)01393-9","volume":"340","author":"M Tatsumi","year":"1997","unstructured":"Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340(2\u20133):249\u201358.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"74_CR22","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1046\/j.1471-4159.1995.64062792.x","volume":"64","author":"DR Gehlert","year":"1995","unstructured":"Gehlert DR, Schober DA, Gackenheimer SL. Comparison of (R)-[3H]tomoxetine and (R\/S)-[3H]nisoxetine binding in rat brain. J Neurochem. 1995;64(6):2792\u2013800.","journal-title":"J Neurochem"},{"issue":"1","key":"74_CR23","first-page":"61","volume":"222","author":"DT Wong","year":"1982","unstructured":"Wong DT, Threlkeld PG, Best KL, et al. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther. 1982;222(1):61\u20135.","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl. 8","key":"74_CR24","first-page":"32","volume":"67","author":"TE Wilens","year":"2006","unstructured":"Wilens TE. Mechanism of action of agents used in attention-deficit\/hyperactivity disorder. J Clin Psychiatry. 2006;67(Suppl. 8):32\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"74_CR25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1089\/cap.2006.16.699","volume":"16","author":"CR Sumner","year":"2006","unstructured":"Sumner CR, Schuh KJ, Sutton VK, et al. Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. J Child Adolesc Psychopharmacol. 2006;16(6):699\u2013711.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"74_CR26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4088\/PCC.v06n0204","volume":"6","author":"L Viktrup","year":"2004","unstructured":"Viktrup L, Pangallo BA, Detke MJ, et al. Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence. Prim Care Companion J Clin Psychiatry. 2004;6(2):65\u201373.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"9","key":"74_CR27","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.chi.0000131135.70992.58","volume":"43","author":"AM Scharko","year":"2004","unstructured":"Scharko AM. Selective serotonin reuptake inhibitor-induced sexual dysfunction in adolescents: a review. J Am Acad Child Adolesc Psychiatry. 2004;43(9):1071\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"74_CR28","unstructured":"CONCERTA\u00ae (methylphenidate HCl) extended-release tablets CII. US prescribing information. Titusville: Ortho-McNeil-Janssen Pharmaceuticals; 2010."},{"key":"74_CR29","unstructured":"Vyvanse (lisdexamfetamine dimesylate) capsule. US prescribing information. Wayne: Shire LLC; 2012."},{"key":"74_CR30","unstructured":"Adderall (dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate) tablet. US prescribing information. Wayne: Shire US Inc.; 2006."},{"key":"74_CR31","unstructured":"Edronax (reboxetine) 4 mg tablets: summary of product characteristics. Kent: Pharmacia Limited; 2011."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-013-0074-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-013-0074-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-013-0074-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T13:40:22Z","timestamp":1645796422000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-013-0074-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,18]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1007\/s40264-013-0074-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,18]]}}}